IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma Authors: Lakshmi Nayak, Christian Grommes, Charles Psoinos, Frederic J Reu, Akira Takazawa, Mayur Uttarwar, Binfeng Xia, Luis A Carvajal, Soojin Kim, Matthew L Sherman, Tracy T Batchelor Published: 2026 ABSTRACT ABSTRACTPrimary central nervous system lymphoma (PCNSL) is a rare, highly aggressive form of non-Hodgkin lymphoma. Although initial responses to the guideline-recommended first-line high-dose methotrexate induction treatment are high, some patients have refractory disease and most experience relapse. Approved therapies for relapsed or refractory (R/R) PCNSL are limited in the US, and there are none in Europe, creating an urgent unmet need for effective treatments. Tirabrutinib is a highly potent and selective second-generation Bruton tyrosine kinase inhibitor approved in Japan, Taiwan, and South Korea for patients with R/R PCNSL. Here, we describe the rationale and design of IGNITE (ONO-4059-17), an ongoing, phase III, multiregional, open-label, randomized study of tirabrutinib vs rituximab and temozolomide combination therapy in R/R PCNSL. The primary endpoint is progression-free survival based on blinded independent review committee (BIRC) per International PCNSL Collaborative Group (IPCG) criteria. Key secondary endpoints are overall response rate based on BIRC per IPCG criteria and overall survival. Safety will be assessed by the incidence and severity of treatment-emergent adverse events.Clinical trial registration: www.clinicaltrials.gov identifier is NCT07104032.KEYWORDS: Tirabrutinib, primary central nervous system lymphoma, relapsed/refractory, clinical trial, protocol Introduction Primary central nervous system lymphoma (PCNSL) is a rare and highly aggressive non-Hodgkin lymphoma that accounts for approximately 2%–4% of all newly diagnosed central nervous system (CNS) tumors, and is localized to the brain, spinal cord, cerebrospinal fluid, and/or eyes [1–3]. PCNSL is diagnosed in approximately 1500 people each year in the US, and the median age at diagnosis is 69 years [4,5]. The prognoses for patients with PCNSL are generally poor, with a median progression-free survival (PFS) of 11 months and a median overall survival (OS) of 25 months after first-line treatment [6]. The guideline-recommended first-line treatment is high-dose methotrexate (HD-MTX) induction, which has demonstrated high overall response rates (ORRs) [6–8]. Subsequent consolidation therapies that include autologous stem cell transplantation show promising efficacy but are only recommended in patients <60–70 years or those with adequate organ function due to the risk of acute toxicity [6,9]. However, up to 30% of patients have disease that does not respond to treatment or quickly progresses (refractory disease) [6,10,11]. Additionally, up to 45% experience relapse within 5 years. For patients with contraindications to HD-MTX, the combination of temozolomide and rituximab (R-TMZ) may be administered, which demonstrated moderate clinical activity in PCNSL with limited toxicity in a phase II clinical trial [7,12]. R-TMZ is also an option for patients whose disease is refractory to or relapses after response to HD-MTX [7,8,12]. Relapsed or refractory (R/R) PCNSL carries a poor prognosis, with median OS ranging from 3.5 to 20 months depending on treatment approach and setting, as well as patient-related factors like age and performance status [11,13–15]. There are no approved therapies for R/R PCNSL in Europe, and only one was recently approved in the US (the chimeric antigen receptor [CAR] T-cell therapy axicabtagene ciloleucel) based on a small study that included 13 participants with PCNSL. While this change represents meaningful progress for patients, the value of CAR T-cell therapy in PCNSL is not yet fully defined, and there remains an urgent unmet need for approved therapies for R/R PCNSL. In PCNSL, acquired mutations lead to aberrant B-cell receptor (BCR) and toll-like receptor (TLR) signaling that constitutively activates key oncogenic pathways, including the nuclear factor-κB (NF-κB) pathway (Figure 1(a)) [16,17]. Both BCR and TLR activation lead to the recruitment of Bruton tyrosine kinase (BTK), a non-receptor protein tyrosine kinase which activates the NF-κB pathway and other transcription factors through various mechanisms including phospholipase C-γ2 and mitogen-activated protein kinase cascades [17,18]. This pivotal role as a mediator of BCR-TLR signaling makes BTK a promising therapeutic target in PCNSL [18,19]. BTK inhibitors are small molecules that can cross the blood-brain barrier and bind to the active site of BTK [20]. The first-generation BTK inhibitor ibrutinib is often used as an off-label treatment option in R/R PCNSL [21]. Despite high response rates, ibrutinib monotherapy has a relatively short duration of response of approximately 6 months, and adverse events such as atrial fibrillation, bleeding, and fungal infections remain a concern [21,22]. PCNSL pathogenesis (a) and BTK inhibition by tirabrutinib (b). Abbreviations: BCR, B-cell receptor; BLNK, B-cell linker; BTK, Bruton tyrosine kinase; CD, cluster of differentiation; MAPK, mitogen-activated protein kinase; MYD88, myeloid differentiation gene 88; NF-κB, nuclear factor-κB; PCNSL, primary central nervous system lymphoma; PLCγ2, phospholipase C γ2; SYK, spleen tyrosine kinase; TLR4, toll-like receptor 4. Tirabrutinib is a highly selective and potent second-generation BTK inhibitor (Figure 1(b)). In vitro, tirabrutinib demonstrated irreversible binding to BTK, as well as greater selectivity for BTK compared to the previous generation [23], which offers the potential for improved tolerability with fewer adverse events associated with off-target binding [21,24,25]. The demonstrated efficacy and safety of tirabrutinib in an open-label phase I/II trial conducted in Japan [26] served as the basis of its approval for R/R PCNSL in Japan, Taiwan, and South Korea. In part A of the PROSPECT phase II study conducted in the US, patients with R/R PCNSL treated with tirabrutinib demonstrated an ORR of 67%, median duration of response of 9.3 months, and complete response (CR) rate (CR + unconfirmed CR [CRu]) of 44% in the primary results [27]. Patients in PROSPECT achieved rapid responses (median time to response, 1.0 month), and most were able to reduce or discontinue corticosteroid use. Furthermore, tirabrutinib was generally well tolerated without any cases of atrial fibrillation, and the most frequent treatment-emergent adverse events (TEAEs; ≥25%) were fall (35%), fatigue (31%), anemia (31%), lymphopenia (27%), headache (25%), and diarrhea (25%) [27]. These findings support further evaluation of tirabrutinib in patients with R/R PCNSL. Here, we describe the study design of IGNITE (NCT07104032, registered July 29, 2025), an ongoing, phase III, multiregional, open-label, randomized study of tirabrutinib vs R-TMZ combination therapy in participants with R/R PCNSL (Figure 2). IGNITE study design. aRelapsed disease was defined as disease recurrence in patients who achieved a response (CR, CRu, or PR) to prior treatment. Refractory disease was defined as disease in patients whose best response to the last treatment was stable disease or progressive disease. bProgressive disease as determined by BIRC according to International PCNSL Collaborative Group criteria. cIncludes safety follow-up 28 days after last dose, disease follow-up every 8 weeks thereafter, and survival follow-up every 3 months thereafter. Disease follow-up only includes patients without disease progression that discontinued study drug for safety or reasons other than withdrawal of consent, and visits will continue until the start of subsequent anticancer therapy for PCNSL or disease progression, whichever occurs first. Abbreviations: BIRC, blinded independent review committee; CR, complete response; CRu, unconfirmed CR; EOT, end of treatment; PCNSL, primary central nervous system lymphoma; PR, partial response; QD, once daily; R/R, relapsed or refractory; R-TMZ, combination therapy with rituximab and temozolomide. Methods Participants Approximately 132 adult participants will be enrolled from sites in the US and globally (trial sites can be found on ClinicalTrials.gov as they are added). Eligible participants must be ≥18 years at the time of informed consent and have a pathologically confirmed diagnosis of R/R B-cell PCNSL previously treated with at least one HD-MTX–based therapy (Table 1). Participants must have at least one bidimensionally measurable brain lesion with a diameter ≥1 cm × ≥1 cm using gadolinium-enhanced magnetic resonance imaging and an Eastern Cooperative Oncology Group performance status ≤2 at screening. Individuals with non–B-cell PCNSL, isolated intraocular PCNSL, or spinal PCNSL with no brain lesions will be excluded. Additional key exclusion criteria include the systemic presence of lymphoma, disease that is refractory to temozolomide-containing regimens with or without rituximab in the last PCNSL treatment, concomitant systemic corticosteroid exposure within 14 days before starting study drug (except for the equivalent of up to 10 mg/day of prednisone for a disease other than PCNSL, or the equivalent of up to 50 mg/day of prednisone [8 mg/day dexamethasone] for participants with lesions of the brain and/or spinal cord), and prior BTK inhibitor treatment. Complete inclusion and exclusion criteria are provided in Table 1. Table 1.Eligibility criteria.Inclusion criteriaWritten informed consent by the participant or legal authorized representative prior to screeningMale or female age ≥18 years at the time of informed consentPathologically confirmed diagnosis of B-cell PCNSLR/R B-cell PCNSL with ≥1 prior HD-MTX–based therapy for PCNSLAt least one bidimensionally measurable brain lesion with a minimum diameter ≥1 cm × ≥1 cm in gadolinium-enhanced MRI based on local read within 14 days before starting study drugECOG PS ≤2Life expectancy of 3 months or longerAdequate bone marrow, renal, and hepatic function at screening by central laboratory analysisFemale participants of childbearing potential must have a negative pregnancy test prior to the first dose of study drug and agree to comply with contraceptive requirementsMale participants must agree to comply with contraceptive requirementsExclusion criteriaIntraocular PCNSL or spinal PCNSL with no brain lesionsAllergy to contrast agents in contrast-enhanced MRI or contraindication to MRINon–B-cell PCNSLPresence of systemic lymphomaPrior nitrosoureas within 42 days, cytarabine and cytotoxic therapies other than procarbazine and methotrexate within 28 days, procarbazine within 21 days, or methotrexate within 14 days before starting study drugPrior non-cytotoxic investigational agents (including bispecific antibodies) within 14 days or 5 half-lives, whichever is shorter, before starting study drugPrior investigational cytotoxic agents within 28 days or 5 half-lives, whichever is shorter, before starting study drugPrior autologous stem cell transplant or CAR-T cell therapy within 1 month and allogenic stem cell transplant within 6 months before starting study drugPrior radiotherapy within 14 days before starting study drugPrior major invasive surgery within 28 days before starting study drug, or minor invasive surgery within 7 days before starting study drugPrior BTK inhibitor treatmentRefractory to temozolomide with or without rituximab–containing regimens in the last PCNSL treatmentConcomitant systemic corticosteroid exposure within 14 days before starting study drug, except for:Equivalent of up to 10 mg/day of prednisone for a disease other than PCNSLEquivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone) for participants with lesions of the brain or spinal cord or bothConcomitant warfarin, any other warfarin-derivative anticoagulant or vitamin K antagonists on an ongoing basis, within 7 days or 5 half-lives, whichever is shorter, before starting study drug. Other anticoagulants may be used at the discretion of the investigatorReceived a moderate or strong cytochrome P450 3A4 inducer, including certain herbal medications (eg, St. John’s wort), within 14 days or 5 half-lives plus 6 days, whichever is shorter, before starting study drugActive malignancy other than PCNSL requiring systemic therapyPoorly controlled comorbidity, severe heart disease, severe lung disease, and/or clinically significant liver diseases that could affect protocol compliance or safety or efficacy assessmentsClinically significant bleeding diathesisA 12-lead electrocardiogram demonstrating QTcF >480 ms at screeningActive clinically significant infection requiring systemic therapy and/or hospitalization. Therapy for minor infections such as superficial fungal infections is allowedPrior history of hypersensitivity or anaphylaxis to tirabrutinib, rituximab, or dacarbazine (temozolomide)Prior history of Stevens–Johnson syndrome or toxic epidermal necrolysisMedical history of organ allograftsTests positive for HIV-1 or HIV-2 antibodyPositive HBsAg serology. Participants who are HBsAg negative and hepatitis B core antibody positive with no detectable DNA are eligiblePositive hepatitis C serology. Participants who are hepatitis C antibody positive and negative for hepatitis RNA are eligibleUnable to swallow tablets; have malabsorption, malabsorption syndrome, or a comorbidity that affects gastric function; have undergone complete resection of the stomach or small intestine; have ulcerative colitis or symptomatic inflammatory bowel disease; or have partial or complete intestinal obstructionFemale participants who are pregnant or lactatingUnable to give informed consent due to dementia or other such conditions. Participants found to be incompetent to give informed consent because of their primary disease may be enrolled if a legally authorized representative gives written informed consentParticipants who are found to otherwise not be suitable for the study as determined by the investigatorAbbreviations: BTK, Bruton tyrosine kinase; CAR, chimeric antigen receptor; ECOG PS, Eastern Cooperative Oncology Group performance status; HBsAg, hepatitis B surface antigen; HD-MTX, high-dose methotrexate; HIV, human immunodeficiency virus; MRI, magnetic resonance imaging; PCNSL, primary central nervous system lymphoma; QTcF, QT interval corrected by Fridericia’s formula; R/R, relapsed or refractory. Eligibility criteria. Equivalent of up to 10 mg/day of prednisone for a disease other than PCNSL Equivalent of up to 10 mg/day of prednisone for a disease other than PCNSL Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone) for participants with lesions of the brain or spinal cord or both Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone) for participants with lesions of the brain or spinal cord or both Abbreviations: BTK, Bruton tyrosine kinase; CAR, chimeric antigen receptor; ECOG PS, Eastern Cooperative Oncology Group performance status; HBsAg, hepatitis B surface antigen; HD-MTX, high-dose methotrexate; HIV, human immunodeficiency virus; MRI, magnetic resonance imaging; PCNSL, primary central nervous system lymphoma; QTcF, QT interval corrected by Fridericia’s formula; R/R, relapsed or refractory. Interventions Eligible participants will be randomized 2:1 by a central interactive web response system to receive tirabrutinib or R-TMZ combination therapy in 28-day cycles until treatment end (maximum of 6 cycles in the R-TMZ arm), disease progression as determined by blinded independent review committee (BIRC) according to International PCNSL Collaborative Group (IPCG) criteria, unacceptable toxicity, or withdrawal of consent, whichever comes first (Figure 2). Tirabrutinib 480 mg once daily (continuous dosing) will be administered orally in the fasted state (at least 1 hour before or at least 2 hours after a meal). Rituximab 375 mg/m2 will be administered intravenously on day 1 of each cycle, and 150 mg/m2/day temozolomide will be administered orally on days 1–5 in the fasted state. After cycle 1, the dose of temozolomide can be escalated to 200 mg/m2 if there is no evidence of grade >2 toxicities or reduced to 100 mg/m2 if toxicity is observed. There are no separate populations in the R-TMZ cohort; patients who complete 6 cycles will be considered to have completed treatment, while those who discontinue treatment for disease progression (or any other reason) will be distinguished by the time of discontinuation along with the corresponding reason. Adherence to study drug will be facilitated by site personnel through review of study drug count and reminding of study drug dosing requirements. Randomization will be stratified by age (<70 years vs ≥70 years) and response from last therapy (relapsed vs refractory). Participants may continue to receive study drug as long as it is still being developed to support the indication, and continuation of treatment does not conflict with the sponsor’s right to terminate the study. There is no crossover in this study to allow for better interpretation of OS in each treatment arm. Outcomes and data collection The primary endpoint is PFS per BIRC using IPCG criteria, defined as the time from randomization to the date of first disease progression or death due to any cause, whichever comes first. Key secondary endpoints are ORR based on BIRC per IPCG criteria (the proportion of participants with a best overall response of CR, CRu, or partial response) and OS (defined as the time from randomization until death). Other secondary endpoints per BIRC using IPCG criteria include CR rate (proportion of participants with a best overall response of CR or CRu), best overall response, time to response, time to complete response, duration of response, and disease-free survival. Change from baseline in corticosteroid dose and safety are also secondary endpoints. Safety will be assessed by the incidence and severity of TEAEs, serious adverse events, and the incidence of TEAEs leading to dose reduction, interruption, or discontinuation of study drugs. Study visits for the tirabrutinib arm will occur on days 1 and 15 (±3 days) of cycle 1, on day 1 (±3 days) of cycle 2, on day 1 (±7 days) of cycles 3–36, and on day 1 (±7 days) of every 6 cycles thereafter. For the R-TMZ arm, treatment visits will occur only up to cycle 6, a safety follow-up visit will occur 28 days after the last dose of R-TMZ, and subsequent disease follow-up visits will occur once every 8 weeks (±7 days) until disease progression. Tumor assessments for the tirabrutinib arm will occur at baseline, on day 1 (±3 days) of cycle 2, and on day 1 (±7 days) of cycle 3, every 2 cycles thereafter to cycle 25, and then every 4 cycles thereafter. For the R-TMZ arm, tumor assessments will occur at the same points up to cycle 3, on day 1 (±7 days) of cycle 5, at end of treatment, and every 8 weeks at disease follow-up visits. Statistical analysis The estimated sample size (N ≈ 132) was determined with considerations for powering the analysis of the primary and key secondary endpoints to detect a difference between treatment arms. The primary analysis set for efficacy outcomes will be based on all participants randomized to treatment (intent-to-treat population) and the safety analysis set (participants who received at least 1 dose of study drug) will be used to assess safety. The primary analysis of PFS (primary endpoint) and interim analysis of OS (key secondary endpoint) will be performed when the prespecified number of PFS events occur; the final analysis of OS will be performed once the prespecified number of deaths occur. Time-to-event curves will be generated for PFS and OS using the Kaplan–Meier method; median values, estimated rates at prespecified time points, and corresponding 95% confidence intervals (CIs) will also be derived using Kaplan–Meier methodology. Differences in PFS and OS between treatment arms will be tested using a stratified log-rank test, with strata defined by the randomization factors (age and R/R status from last therapy). Similarly, a stratified Cox proportional hazards model that accounts for the randomization stratification factors will be used to estimate the hazard ratio and corresponding 2-sided 95% CI. The difference in ORR between treatment arms and the odds ratio (and corresponding 95% CIs) will be estimated by the Cochran–Mantel–Haenszel method using the randomization stratification factors. Ethics and dissemination This study is being performed in accordance with the Declaration of Helsinki and is consistent with International Conference on Harmonization and Good Clinical Practice guidelines. Applicable local regulatory requirements are being followed, and the investigators ensure that this study is conducted in full conformity with Regulations for the Protection of Human Subjects of Research. The study is approved by a central institutional review board (Advarra, approval number: Pro00090226) and will be reviewed by applicable local ethics committees and/or review boards for sites outside the US. A data monitoring committee will periodically monitor the safety data from IGNITE and will consist of a biostatistician and at least two clinicians, not employed by the sponsor, with combined expertise in general oncology, PCNSL, practical experience conducting clinical trials, and monitoring safety and efficacy of clinical trials. The investigators ensure that each study participant is fully informed about the nature and objectives of the study and possible risks associated with participation and obtain written informed consent from each participant before any study-specific activity is performed. Results are expected by 2028, and the sponsor will disclose the summary of trial results on public clinical trial registries within the time frame specified by local law or regulation. Conclusions The IGNITE trial aims to evaluate the efficacy and safety of tirabrutinib vs R-TMZ in participants with R/R PCNSL. This randomized study will compare the PFS between tirabrutinib and an active comparator to further confirm the efficacy observed with tirabrutinib in part A of the PROSPECT phase II study [27]. There remains a high unmet therapeutic need for patients with R/R PCNSL with limited approved treatments in the US and none in Europe. The results of this study will help define the global use of tirabrutinib, potentially leading to a new treatment option in the US and other regions that improves tumor response for patients with R/R PCNSL. Acknowledgments The authors thank the participants and their families and caregivers, the investigators, and the investigational site staff of the study. A trial-in-progress abstract and poster were originally presented at the 2025 ASH Annual Meeting and Exposition, December 6–9, 2025, in Orlando, FL, USA. Abstract number: abs25-7112; Poster number: 3703. Funding Statement This manuscript was funded by Deciphera Pharmaceuticals, LLC, a member of ONO Pharma. The study is funded by ONO Pharma in collaboration with Deciphera Pharmaceuticals, LLC (The funder was involved in study design, decision to publish, and the preparation of the manuscript.) Protocol number: [ONO-4059-17]. For inquiries about this trial, please contact Deciphera Pharmaceuticals, LLC (781-209-6400 or clinicaltrial@deciphera.com). Article highlights Primary central nervous system lymphoma (PCNSL) is a rare and highly aggressive non-Hodgkin lymphoma. Primary central nervous system lymphoma (PCNSL) is a rare and highly aggressive non-Hodgkin lymphoma. Initial response rates to the guideline-recommended first-line high-dose methotrexate induction therapy are high. Initial response rates to the guideline-recommended first-line high-dose methotrexate induction therapy are high. However, some patients have refractory disease and a high proportion of patients with responses experience relapse within 5 years. However, some patients have refractory disease and a high proportion of patients with responses experience relapse within 5 years. There are currently no approved treatments for relapsed or refractory (R/R) PCNSL in Europe and only one in the US. There are currently no approved treatments for relapsed or refractory (R/R) PCNSL in Europe and only one in the US. Tirabrutinib is a highly potent and selective Bruton tyrosine kinase inhibitor approved for the treatment of R/R PCNSL in Japan, Taiwan, and South Korea. Tirabrutinib is a highly potent and selective Bruton tyrosine kinase inhibitor approved for the treatment of R/R PCNSL in Japan, Taiwan, and South Korea. In the PROSPECT phase II study conducted in the US, tirabrutinib demonstrated robust and durable efficacy and was generally well tolerated. In the PROSPECT phase II study conducted in the US, tirabrutinib demonstrated robust and durable efficacy and was generally well tolerated. Based on these results, the multiregional, open-label, randomized IGNITE phase III study aims to assess the efficacy and safety of tirabrutinib vs rituximab and temozolomide combination therapy in patients with R/R PCNSL. Based on these results, the multiregional, open-label, randomized IGNITE phase III study aims to assess the efficacy and safety of tirabrutinib vs rituximab and temozolomide combination therapy in patients with R/R PCNSL. The primary endpoint is progression-free survival based on blinded independent review committee (BIRC) per International PCNSL Collaborative Group (IPCG) criteria. The primary endpoint is progression-free survival based on blinded independent review committee (BIRC) per International PCNSL Collaborative Group (IPCG) criteria. Key secondary endpoints are overall response rate based on BIRC per IPCG criteria and overall survival. Key secondary endpoints are overall response rate based on BIRC per IPCG criteria and overall survival. Enrollment for the study is ongoing. Enrollment for the study is ongoing. Disclosure statement Lakshmi Nayak reports research support from the Leukemia and Lymphoma Society and NIH; royalties from Wolters Kluwer (UpToDate); consulting for Brave Bio, Curis, Genmab, and ONO Pharma; Honoraria from AstraZeneca and ONO Pharma; expert testimony for Versed and the US Department of Justice; travel support from ONO Pharma; advisory board roles with Curis; Kite/Gilead Sciences, Inc.; Miltenyi; ONO Pharma; and clinical trial support from AstraZeneca, Curis, Kazia, Merck, and ONO Pharma. Christian Grommes reports consulting/advisory roles for BTG, Curis, ONO Pharma, and Roche and a speakers bureau position for ONO Pharma and support from the National Institutes of Health (Grant P30-CA008748).. Charles Psoinos reports employment for Deciphera Pharmaceuticals, LLC. Frederic J. Reu reports employment for Deciphera Pharmaceuticals, LLC. Akira Takazawa reports employment for ONO Pharma. Mayur Uttarwar reports employment for Deciphera Pharmaceuticals, LLC. Binfeng Xia reports employment for Deciphera Pharmaceuticals, LLC. Luis Carvajal reports employment for Deciphera Pharmaceuticals, LLC. Soojin Kim reports employment for Deciphera Pharmaceuticals, LLC. Matthew L. Sherman reports employment for Deciphera Pharmaceuticals, LLC; a leadership role with Deciphera Pharmaceuticals, LLC; travel support from Deciphera Pharmaceuticals, LLC; and patents/royalties/other intellectual property from Deciphera Pharmaceuticals, LLC (inventor in pending patents at Deciphera Pharmaceuticals, LLC; transferred the rights to Deciphera Pharmaceuticals, LLC; has not received [and will not receive] any royalties). Tracy T. Batchelor reports royalties from Oxford University Press and UpToDate and institutional research support from ONO Pharma. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing and editorial support was provided by Steven Walker, PhD, CMPP, of Red Nucleus, and was funded by Deciphera Pharmaceuticals, LLC. Reviewer disclosures Peer reviewers on this manuscript have no relevant financial or other relationships to disclose. Ethical declaration This study is being performed in accordance with the Declaration of Helsinki and is consistent with International Conference on Harmonization and Good Clinical Practice guidelines. Applicable local regulatory requirements are being followed, and the investigators ensure that this study is conducted in full conformity with Regulations for the Protection of Human Subjects of Research. The study is approved by a central institutional review board (Advarra, approval number: Pro00090226). The investigators ensure that each study participant is fully informed about the nature and objectives of the study and possible risks associated with participation and obtain written informed consent from each participant before any study-specific activity is performed. Data availability statement Qualified scientific and medical researchers will be able to address requests for de-identified individual participant data that underlie the results from IGNITE at info@deciphera.com. Proposals for data will be evaluated and approved by Deciphera Pharmaceuticals, LLC, at its sole discretion. All approved researchers must sign a data access agreement before accessing the data. Data will be available as soon as possible but no later than within 1 year of the acceptance of the article for publication and for 3 years after article publication. Deciphera Pharmaceuticals, LLC, will not share data from identified participants or a data dictionary. References Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers. Associated Data Data Availability Statement Qualified scientific and medical researchers will be able to address requests for de-identified individual participant data that underlie the results from IGNITE at info@deciphera.com. Proposals for data will be evaluated and approved by Deciphera Pharmaceuticals, LLC, at its sole discretion. All approved researchers must sign a data access agreement before accessing the data. Data will be available as soon as possible but no later than within 1 year of the acceptance of the article for publication and for 3 years after article publication. Deciphera Pharmaceuticals, LLC, will not share data from identified participants or a data dictionary.